Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T

Journal of bone and mineral metabolism1 Nov 2008Cited by 34 (Europe PMC)

PMID18979163DOI10.1007/s00774-008-0871-3PepBankPUB-18979163

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, lumbar spine BMD increased with increasing teriparatide dose compared with placebo.
In plain wordsIn Japanese women with osteoporosis, spine bone density increased with higher teriparatide doses compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD dose response
Study
n = 154
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10, 20 and 40 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Teriparatide (10-microg, 20-microg, and 40-microg doses) showed a statistically significant increase with increasing treatment dose as assessed by the percent change of lumbar spine BMD from baseline to endpoint using Williams' test when compared with placebo (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916301
02HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, lumbar spine BMD increased by 6.40% from baseline with teriparatide.
In plain wordsIn Japanese women with osteoporosis, spine bone density increased by 6.40% from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at 20 microg
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Lumbar spine BMD change
6.4%
20 microg
SD
4.76%
lumbar spine BMD change at 20 microg
Source sentences
Summary
The mean (+/-SD) percent change in lumbar spine, femoral neck, and total hip BMD with the 20-microg dose from baseline to endpoint was 6.40% +/- 4.76%, 1.83% +/- 7.13%, and 1.91% +/- 3.60%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916302
03HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, femoral neck BMD increased by 1.83% from baseline with teriparatide.
In plain wordsIn Japanese women with osteoporosis, femoral neck bone density increased by 1.83% from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD at 20 microg
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Femoral neck BMD change
1.83%
20 microg
SD
7.13%
femoral neck BMD change at 20 microg
Source sentences
Summary
The mean (+/-SD) percent change in lumbar spine, femoral neck, and total hip BMD with the 20-microg dose from baseline to endpoint was 6.40% +/- 4.76%, 1.83% +/- 7.13%, and 1.91% +/- 3.60%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916303
04HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, total hip BMD increased by 1.91% from baseline with teriparatide.
In plain wordsIn Japanese women with osteoporosis, total hip bone density increased by 1.91% from baseline with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD at 20 microg
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Total hip BMD change
1.91%
20 microg
SD
3.6%
total hip BMD change at 20 microg
Source sentences
Summary
The mean (+/-SD) percent change in lumbar spine, femoral neck, and total hip BMD with the 20-microg dose from baseline to endpoint was 6.40% +/- 4.76%, 1.83% +/- 7.13%, and 1.91% +/- 3.60%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916304
05HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, teriparatide produced rapid and sustained PINP increases.
In plain wordsIn Japanese women with osteoporosis, teriparatide rapidly and persistently increased the PINP bone formation marker.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Rapid and sustained increases in bone formation markers [type I procollagen N-terminal propeptide (PINP), type I procollagen C-terminal propeptide (PICP), and bone-specific alkaline phosphatase (BAP)],
3 context sentences(design, population, supporting numbers)
Summary · context
were observed for the teriparatide treatment groups (20-microg, 40-microg),
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916305
06HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, teriparatide produced rapid and sustained PICP increases.
In plain wordsIn Japanese women with osteoporosis, teriparatide rapidly and persistently increased the PICP bone formation marker.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePICP
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Rapid and sustained increases in bone formation markers [type I procollagen N-terminal propeptide (PINP), type I procollagen C-terminal propeptide (PICP), and bone-specific alkaline phosphatase (BAP)],
3 context sentences(design, population, supporting numbers)
Summary · context
were observed for the teriparatide treatment groups (20-microg, 40-microg),
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916306
07HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, teriparatide produced rapid and sustained BAP increases.
In plain wordsIn Japanese women with osteoporosis, teriparatide rapidly and persistently increased the BAP bone formation marker.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBAP
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Rapid and sustained increases in bone formation markers [type I procollagen N-terminal propeptide (PINP), type I procollagen C-terminal propeptide (PICP), and bone-specific alkaline phosphatase (BAP)],
3 context sentences(design, population, supporting numbers)
Summary · context
were observed for the teriparatide treatment groups (20-microg, 40-microg),
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916307
08HumanRandomized controlled trialEfficacy outcome
In Japanese women with osteoporosis, teriparatide produced late increases in CTX.
In plain wordsIn Japanese women with osteoporosis, teriparatide increased the CTX bone resorption marker later during treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCTX
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
followed by late increases in a bone resorption marker [type I collagen cross-linked C-telopeptide (CTX)], were observed for the teriparatide treatment groups (20-microg, 40-microg),
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
Report a problemFND-1897916308

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther
In Japanese women with osteoporosis, daily self-injection treatment achieved optimal adherence across the trial.
In plain wordsIn Japanese women with osteoporosis, adherence to daily self-injection treatment was optimal across the trial.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTreatment adherence
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Source sentences
Summary
Optimal adherence was achieved by this daily self-injection treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1897916309
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
In Japanese women with osteoporosis, most reported adverse events were mild to moderate during the teriparatide trial.
In plain wordsIn Japanese women with osteoporosis, most reported adverse events were mild to moderate during the teriparatide trial.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableAdverse event severity
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Regarding safety, most of the adverse events were mild to moderate in severity.
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1897916310
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
In Japanese women with osteoporosis, no study drug- or procedure-related serious adverse events occurred during treatment.
In plain wordsIn Japanese women with osteoporosis, no serious adverse events related to the study drug or procedures occurred during treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableRelated serious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
No study drug-or study procedure-related serious adverse events were reported during the treatment period.
2 context sentences(design, population, supporting numbers)
Summary · context
The dose-response efficacy and safety with three doses of teriparatide and placebo was assessed, using once-daily subcutaneous injections for 24 weeks, in Japanese postmenopausal women with osteoporosis
Summary · context
In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1897916311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.